Clinical trials: Endocrine and Metabolic Diseases
Type 2 Diabetes
Diamel in the Treatment of Type 2 Diabetic Patients Receiving Insulin Therapy
The purpose of this study is to assess the efficacy of Diamel (dietary supplement) administration in the treatment of patients with type 2 diabetes receiving insulin therapy.
- Trial name
- NCT00994266
- Testing
- Diamel
- Where
- Cuba
- Volunteers
- 116 people
- Sponsor
- Catalysis SL
Diabetes Mellitus, Type 2
Placebo Controlled Metformin and Sulfonylurea Combination Study in Patients With Type 2 Diabetes (0767-025)
The purpose of this study is to compare how MK0767 and metformin and sulfonylurea therapy lower blood glucose in patients with inadequate glycemic control This is an early phase trial and some specific protocol information is in…
- Trial name
- NCT00543751
- Testing
- MK0767
- Volunteers
- 610 people
- Sponsor
- Merck Sharp & Dohme LLC
Third Degree Burns, Diabetes
Study of ST266 in Diabetic Subjects With Deep Burns Managed With Skin Grafts
This study is a randomized, double blind, placebo controlled trial at a single site. The primary objective is to evaluate the safety of ST266 in diabetic subjects with deep burns.
- Trial name
- NCT01715012
- Testing
- ST266, Saline
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
Diabetes Mellitus Type 1
Measuring and Monitoring Blood Glucose Levels Utilizing Non-invasive Blood Glucose Monitoring Device
Adequate glycemic control in patients with Diabetes Mellitus (DM) is a desired therapeutic goal that can be achieved with a true non-invasive device offering the likelihood of continuous glucose monitoring.
- Trial name
- NCT01508065
- Testing
- Glucometer CGM-305
- Where
- 2 sites in Israel
- Volunteers
- 20 people
- Sponsor
- GlucoVista
Foot Ulcer, Diabetes
Safety and Efficacy Study of an Interactive Wound Dressing (KC002) for the Treatment of Diabetic Foot Ulcers
The objective of this study is to determine the safety and effectiveness of a device (the KC-002 interactive wound dressing) in the promotion of healing in diabetic foot ulcers as compared with a conventional wound therapy…
- Trial name
- KC-002PT (NCT00330265)
- Testing
- KC-002, Conventional Wound Therapy
- Where
- 21 sites in United States
- Volunteers
- 300 people
- Sponsor
- KeraCure
Diabetes, Diabetes Mellitus, Type 2
The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to investigate the efficacy and safety of liraglutide compared to sitagliptin, both as add-on to metformin in Chinese subjects with type 2 diabetes inadequately controlled…
- Trial name
- NCT02008682
- Testing
- liraglutide, sitagliptin
- Where
- 25 sites in China
- Volunteers
- 368 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of Canagliflozin (TA-7284) in combination with Insulin in patients with type 2 Diabetes for 16 weeks administration.
- Trial name
- NCT02220920
- Testing
- Canagliflozin (TA-7284), Insulin
- Where
- 7 sites in Japan
- Volunteers
- 146 people
- Sponsor
- Tanabe Pharma Corporation
Hypertension, Vascular Diseases
Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension
The purpose of the SPYRAL SWYFT sub-study is to evaluate whether renal denervation with the Symplicity Spyral system performed in the main and first order branch renal arteries yields a shorter procedure time and is as effective…
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
- Trial name
- SWYFT (NCT07115953)
- Testing
- Symplicity Spyral™ multi-electrode renal denervation system
- Where
- 21 sites in Australia, Belgium and 7 more
- Volunteers
- 130 people
- Sponsor
- Medtronic Vascular
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation
This trial is conducted in Europe and North America. The aim of this trial is to investigate if liraglutide treatment can increase the proportion of insulin-independent subjects one year after islet cell transplantation who…
- Trial name
- NCT01206101
- Testing
- liraglutide
- Where
- 16 sites in United States, Canada and 4 more
- Volunteers
- 3 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus: Type 1
A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro
28 subjects to be enrolled for a screening period, 3 dosing visits \& a follow-up visit. Visits 2 and 3 dosing of TI Inhalation Powder, cross over between two 15 U cartridges and one 30 U cartridge.
- Trial name
- NCT00662857
- Testing
- Technosphere® Insulin Inhalation Powder, Technosphere Insulin® Inhalation Powder, RAA Population
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus Type 2
A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
This 6 arm study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of multiple doses and regimens of a GLP-1 analogue in patients with type 2 diabetes who are treated with a stable dose of metformin.
- Trial name
- NCT00423501
- Testing
- taspoglutide
- Where
- 49 sites in United States, Australia and 8 more
- Volunteers
- 306 people
- Sponsor
- Hoffmann-La Roche
Type II Diabetes Mellitus
Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan
Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan.
- Trial name
- NCT03084965
- Where
- 8 sites in Taiwan
- Volunteers
- 1,987 people
- Sponsor
- AstraZeneca
Hyperglycemia
Feasibility Study to Evaluate Safety and Device Performance of the Hospital Glucose Management System (HGMS)
The purpose of this study is to assess safety and device performance of the Medtronic Hospital Glucose Management System (HGMS) for up to 72-hours.
- Trial name
- MAHI (NCT01763567)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Medtronic MiniMed, Inc.
Congenital Adrenal Hyperplasia
Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia
This study is a randomized, double-blind, active-controlled, phase III study of Chronocort® compared with immediate-release hydrocortisone replacement therapy in participants aged 16 years and over with Congenital Adrenal…
- Trial name
- CONnECT (NCT05063994)
- Testing
- Chronocort, Cortef
- Where
- 21 sites in United States, France and 1 more
- Volunteers
- 55 people
- Sponsor
- Neurocrine UK Limited
Diabetes, Healthy
Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers
This trial is conducted in Europe. The aim of this trial is to test for bioequivalence of the phase 3a formulation of liraglutide (formulation 4) and the liraglutide formulation planned for phase 3b trials (final formulation 4).
- Trial name
- NCT01515553
- Testing
- liraglutide
- Where
- Sweden
- Volunteers
- 22 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Primary Objective: The purpose of this study was to compare insulin glargine/ lixisenatide fixed ratio combination (FRC) versus insulin glargine on glycemic control over 24 weeks, as evaluated by glycosylated hemoglobin (HbA1c)…
- Trial name
- NCT01476475
- Testing
- Insulin glargine /lixisenatide Fixed Ratio Combination, Insulin glargine, Metformin (Background drug)
- Where
- 70 sites in United States, Chile and 11 more
- Volunteers
- 323 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.
The aim of this study is to assess how safe the study drug is and how well a participant tolerates it after a single oral (taken by mouth) dose.
- Trial name
- NCT03617081
- Testing
- NNC0113-2023
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy
The study design of this trial is double blind, parallel-group, randomized, Placebo controlled study.
- Trial name
- T2DM (NCT01805830)
- Testing
- MP513
- Where
- South Korea
- Volunteers
- 189 people
- Sponsor
- Handok Inc.
Chronic Kidney Disease, Type 2 Diabetes
A Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus
A Phase 2 study of RTA 402 in Chronic kidney disease (CKD) patients with type 2 diabetes mellitus.
- Trial name
- NCT01574365
- Testing
- RTA 402
- Where
- Japan
- Volunteers
- 53 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Type 2 Diabetes Mellitus
Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
The purpose of this study is to investigate the effect of bexagliflozin compared to sitagliptin as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03115112
- Testing
- Bexagliflozin, Sitagliptin
- Where
- 56 sites in United States, Czechia and 4 more
- Volunteers
- 386 people
- Sponsor
- Theracos
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.